ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia

WEDNESDAY, Dec. 13, 2023 -- For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news